The detection of genetic loci associated with Alzheimer's disease (AD) requires large 32 numbers of cases and controls because variant effect-sizes are mostly small. We 33 hypothesized that variant effect-sizes should increase when individuals who represent the 34 extreme ends of a disease spectrum are considered, as their genomes are assumed to be 35 maximally enriched or depleted with disease-associated genetic variants.
3) comparing normal AD cases with extreme (centenarian) controls (NA vs. EC). To 148 calculate variant effect-sizes, we used logistic regression models correcting for population 149 stratification (principal components 1 to 6). 37, 38 We calculated odds ratios (OR) relative to the 150 HRC alternative allele assuming additive genetic effects, and estimated 95% confidence 151 intervals (CIs).
153
We estimated the change in effect-size relative to reported effect sizes (!) as follows: 
188
The average change in effect-size across all ;=29 tested variants is calculated as follows:
189
190
Confidence intervals and probability of divergence between ! "#$ and previously reported 191 effect-sizes were estimated by sampling (S=10,000, two-tailed p-value). was on average 29.5 years higher than for previously published controls ( Figure 1 ).
207

Effect of comparing extreme cases and centenarian controls
In a genetic comparison of extreme AD cases and centenarian controls (EA-EC comparison) 209 the average effect-size over all 29 genetic variants was 1.90-fold increased relative to the 210 effect-sizes reported in published studies (! ./#.0 = 1.90±0.29; p = 9.0x10 -4 ) ( Figure 3) . For 211 21 out of 29 variants, we observed an increased effect size (! ./#.0 % > 1), which is 212 significantly more than expected by chance (p = 1.2x10 -2 ) ( Figure 2 and 
229
Overall, for 7 variants, the effect size was significantly increased relatively to the previously 230 reported effect-sizes (Table 2) , in or near genes APOE ε2 (2.2-fold, p = 1.4x10 -7 ), APOE ε4
231
(2.0-fold, p = 1.5x10 -9 ), SLC24A4-RIN3 (4.5-fold, p = 1.6x10 -3 ), ECHDC3 (4.6-fold, p = 232 1.1x10 -2 ), PLCG2 (3.3-fold p = 1.4x10 -2 ), NME8 (3.9-fold, p = 1.7x10 -2 ) and MEF2C (-1.9-233 fold, p = 1.8x10 -2 ). Variants with significant effect-size changes, were also more likely to be 234 associated with AD in a comparison of extreme cases and centenarians. The association with AD reached nominal significance (p<0.05) in 10 out of 21 variants with a changed 236 effect-size ( Table 2 ). Next to APOE ε4 (log *+ ./#.0 /12. 45 = 2.1, SE = 0.17, p = 1.3×10 -33 ) and 237 APOE ε2 (log *+ ./#.0 /12. 4$ = -1.8, p = 3.2×10 -21 ), variants in or near these genes were 238 significantly associated with AD: SCL24A4-RIN3, PLCG2, ECHDC3, NME8, BIN1, 239 ZCWPW1, ABCA7 (A>G) and HLA-DRB1 (Table 2) .
241
Effect of using extreme AD cases
242
The average effect-size in a comparison of extreme AD cases with normal controls (EA vs.
243
NC) did not significantly change relative to the previously reported effect-sizes (! ./#60 = 244 0.94±0.12, p=6.8x10 -1 ) ( Figure 3) . For 14 individual variants, we observed an increased 245 effect size, which was expected by chance (p=0.5), Figure S1 and Table S2 ). The effect size 246 was significantly increased for APOE ε4 variant (1.3-fold, p = 1.4x10 -5 ), and nominally 247 significant for APOE-ε2 (1.4-fold, p = 1.7x10 -2 ).
249
We then separated AD cases into early-onset extreme AD cases (N eEA = 464) and late-onset 250 extreme AD cases (N lEA = 609), and estimated the change in effect-sizes. When using early 251 onset cases the average effect-size was lower relative to previously published effect sizes 252 (! 8./#60 was 0.86±0.16 (p = 7.9x10 -1 ), while for late-onset cases the effect size was similar 253 to published effect sizes (! ,./#60 was 1.01±0.14, p = 4.6x10 -1 ) ( Figure S3 and Table S3 ).
254
We found significant differences between the effect-sizes in early-onset and late-onset AD In a comparison of normal AD cases and extreme (centenarian) controls (NA vs. EC), the 261 effect-size was on average 1.88-fold higher relative to previously reported effect-sizes (! 6/#.0 = 1.88±0.24, p = 1.0x10 -4 ) (Figure 3) . This was almost identical to the average 263 increase in effect-size when we compared the extreme cases with centenarian controls 264 (! ./#.0 = 1.90±0.29; p = 9.0x10 -4 ) (Figure 3) . At the variant level, the change in effect-sizes 265 was similar in both analyses, with the exception of the rare TREM2 (R47H) variant, whose 266 effect-size increase was higher in the comparison with the extreme cases (but with high 267 confidence intervals) ( Figure S4-A) .
269
In further concordance with the comparison of the extreme phenotypes, we observed an 
271
which is more than expected by chance (p = 2.7x10 -4 ) ( Figure S2 and Table S2 ). We found a 272 significant increase in effect-size for variants in or near APOE-ε2 (1.7-fold, p < 5x10 -5 ),
273
APOE-ε4 (1.7-fold, p < 5x10 -5 ), NME8 (4.5-fold, p = 3.5x10 -3 ), SLC24A4-RIN3 (3.9-fold, p = 274 4.5x10 -3 ) and PLCG2 (2.9-fold, p = 1.9x10 -2 ). In line with this, for almost all variants 275 individually, the extreme controls contributed more to the effect size change in the extremes-276 comparison, than the extreme cases ( Figure S4-B ).
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Discussion
280
In this study, we found that the effect sizes of 29 variants previously identified in genetic 
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In a comparison of AD cases (either normal or extreme) with centenarian controls, we 291 observed significant effect-size increases for variants in or near PLCG2, NME8, ECHDC3,
292
SLC24A4-RIN3, . This suggests that the tested variants or loci might 293 contribute to the long-term preservation of cognitive health and/or to longevity in general.
294
PLCG2 and NME8 are implicated in immunological processes, 8, 43 while SLC24A4, ECHDC3 295 and APOE are involved in lipid and cholesterol metabolism. 17, 44, 45 Both these processes 296 were previously associated with longevity, 46,47 such that an overlapping etiology of 297 maintained cognitive health and maintained overall health may contribute to the observed 298 increase in effect-size. However, with the exception of the APOE locus, these loci were thus 299 far not associated with longevity in GWAS studies. [48] [49] [50] [51] We speculate that the association 300 might be dependent on the cognitive health in the centenarians of the 100-plus Study 301 cohort. 29 Alternatively, longevity studies may have been underpowered to detect the 302 association of these loci with extreme survival. Future studies will have to establish the 303 mechanism behind the association of these genes with preserved cognitive health. Next to 304 APOE, the HLA-DRB1 locus has been associated with both AD 13 and longevity. 48 However,
305
its most informative variants, rs9271192 for AD and rs34831921 for longevity, are not in 306 linkage disequilibrium, 52 suggesting that these are independent signals.
308
Using extreme cases did not increase the variant effect-sizes relative to published effect-309 sizes, even though most of the extreme cases were biomarker confirmed and their mean 310 age at onset was 8.2 years younger than the mean age at onset in other studies. 7, 8, 13 This
311
suggests that based on the tested genetic variants, the "phenotypically extreme" cases 312 presented in this study were not genetically more extreme than cases presented in other 313 studies.
315
Counter intuitively, in a comparison with normal controls, the variant effect-sizes of early-316 onset AD cases were on average lower than the variant effect-size of late-onset AD cases.
One explanation for this observation may be that the early age at onset may have been 318 driven by rare, high-impact variants, 19 while the disease onset at later ages may depend to a 319 greater extent on more common risk variants, which are tested here. However, at the variant 320 level, we found significant differences between the effect-sizes in early-onset and late-onset 321 cases for variants in/near ZCWPW1 and APOE ε2, and also in -opposite directions-for 322 the variant in MS4A6A. These results are a first indication that these variants may 323 differentially influence age of disease onset, however, future experiments will have to 324 confirm this finding.
326
Here, we find that the majority of the observed increase in effect-size in a genetic case-
327
control study of extreme phenotypes is attributable to the extreme controls. We note that the 328 centenarians used in this study were selected for their preserved cognitive health, which 329 might have further enlarged the effect-size increase for genetic variants that were previously 330 identified for their AD-association. We acknowledge that using centenarians as controls in 331 genetic studies of AD could result in the detection of variants associated with extreme 332 longevity, such that newly detected AD-associations need to be verified in an age-matched 333 AD case-control setting. Nevertheless, the effect-sizes for all but two variants are in the 334 same direction as previously reported, which suggests that the tested AD variants do not 335 have significant pleiotropic activities that counteract their AD-related survival effects.
336
Notably, the two variants with an opposite effect in the comparison of the extremes relative 337 to published effect sizes, in or near MEF2C and FERMT2, also did not associate with AD in 338 our age-matched case-control analysis. This suggests that the AD-association of the MEF2C 339 and FERMT2 variants might be false positive findings in previous studies. This is in line with 340 results from unpublished GWASs of AD in which AD-associations of variants near the 341 MEF2C and FERMT2 genes were not replicated 41,42 (p = 5.4x10 -3 , 41 p = 3.0x10 -4 for 342 MEF2C 42 and p = 1.6x10 -5 for FERMT2 42 variant, with 5.0x10 -8 being the genome-wide 343 significance threshold). An additional strength of our study is that our cohorts of AD patients 344 and controls, were not previously used in the discovery of any of the known AD associated variants; 4-17 we thus provide independent replication in a genetically homogeneous group of 346 individuals, as they all came from one specific population (Dutch).
348
Concluding, in our comparison of cases and controls with extreme phenotypes we found that 349 on average, the effect of AD-related variants in genetic association studies almost doubled, 527 528 
Tables and Figures
543
Weighted mean and (combined) standard deviation of the age at onset for AD cases and age at 544 inclusion for controls. As weights, we used the sample sizes of each GWA study. Note that previous cases (N lEA =609); centenarian controls (N EC =255); normal controls (N NC =1,664). 95% confidence 558 intervals were estimated by random sampling (S=10,000).
